Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings; Javier San Martín; Michael R. McClung; Ethel S. Siris; Richard Eastell

doi:10.1056/nejmoa0809493

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings, Javier San Martín, Michael R. McClung, Ethel S. Siris, Richard Eastell, Ian R. Reid, Pierre Delmas, Holly Brenza Zoog, Matt Austin, Andrea Wang, Štěpán Kutílek, Silvano Adami, José Zanchetta, Cesar Libanati, Suresh Siddhanti...

Massachusetts Medical Society (2009) • Volume 361, Issue 8, Pages 756-765

PDF Available

Abstract

Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)

Quick Actions

Read Full Paper

Publication Info

DOI

10.1056/nejmoa0809493

Language

English

Topic

Bone Metabolism and Diseases

Keywords

Denosumab, Medicine, RANKL, Osteoporosis, Bone resorption, Activator (genetics), RANK Ligand, Monoclonal antibody, Monoclonal, Postmenopausal women, Bone Density Conservation Agents, Internal medicine, Bone mineral, Endocrinology, Postmenopausal osteoporosis, Receptor, Antibody, Immunology

Published

August 11, 2009

Citations

3298 citations

FWCI

91.36

External Resources

DOI Link OpenAlex

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Analysis of Growth of Interventional Techniques inManaging Chronic Pain in the Medicare Population:A 10-Year Evaluation from 1997 to 2006

Suggested Papers

Suggested Papers

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Analysis of Growth of Interventional Techniques inManaging Chronic Pain in the Medicare Population:A 10-Year Evaluation from 1997 to 2006